Hepatitis A virus is a globally prevalent hepatotrophic pathogen.Infection generally results in an acute,self-limiting illness but with the potential for significant morbidity and mortality in a susceptible population.Safe and effective vaccines are currently available in the United States and worldwide.Implementation of successful vaccination programs has allowed for favorable shif ts in the epidemiology of this disease.
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 2.Dagan R, Leventhal A, Anis E, et al.: Incidence of hepatitis A in Israel following universal immunizat ion of toddlers. JAMA 2005, 294:202–210. A report on the remarkable success in controlling hepatitis A infections through HAV vaccinat ions of a targeted population in Israel.PubMedCrossRefGoogle Scholar
- 5.Centers for Disease Control and Prevention:Summary of notifiable diseases,United States,1999.MMWR 1999,48:82–90.Google Scholar
- 8.Centers for Disease Control and Prevention: Prevention of hepatitis At hrough active or passive immunization: recommendations of t he Advisory Committee on Immunization Practices (ACIP).MMWR Recomm Rep 1999,48:1–37. A comprehensive review of HAV clinical features,sur veillance, transmission,and epidemiology,as well as extensive review of vaccine performance.Includes data and rationale for current ACIP vaccination guidelines.Google Scholar
- 9.Centers for Disease Control and Prevention:Hepatitis A vaccination coverage among children 24–35 months —United States,2003.MMWR Morb Mortal Wkly Rep 2005,54:141–144.Google Scholar
- 15.Notice to readers:FDA approval of VAQTA ® (hepatitis A vaccine,inact ivated)for children aged =1 year.http:// www.cdc.gov/ncidod/diseases /hepatitis /a/index.ht m. Accessed October 29,2005.Google Scholar
- 26.Merck &Co.:VAQTA ® (hepat it is A vaccine,inact ivated). In Physicians’ Desk Reference, edn 51.Mont vale, NJ:Medical Economics Co.;1997:1805–1807.Google Scholar
- 27.SmithKline Beecham Biologicals:HAVRI X ® (hepatitis A vaccine,inactivated).In Physicians ’ Desk Reference,,edn 51. Montvale,NJ:Medical Economics Co.;1997:2663–2665.Google Scholar